Epigenomics H1 FY26 net loss narrows to EUR 128,000; revenue rises to EUR 17,000
Reuters2026/09/03 07:02- Epigenomics posted a H1 2026 net loss of EUR 128,000, narrowing from EUR 204,000 a year earlier.
- Revenue rose to EUR 17,000 from EUR 4,000, while other operating income increased to EUR 16,000 from EUR 7,000.
- Other operating expenses fell to EUR 112,000 from EUR 188,000 due to cost-cutting, while personnel expense climbed to EUR 70,000 from EUR 50,000.
- Cash and cash equivalents declined to EUR 277,000 at June 30 from EUR 414,000 at Dec. 31.
- The board expects existing funds to cover costs beyond 2027, forecasting a 2026 net loss of EUR 0.2 million to EUR 0.5 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canada Says Oil Sands Have Policy Support Needed To Boost Output
European Central Bank Governing Council Member Nagel: AI Will Be a "Touchstone" for Europe’s Future
Nagel stated in Berlin that artificial intelligence (AI) will become a "touchstone" for testing whether Europe can unite and fully unleash its potential.
Cameo Resources appoints Duranya Sebabili director, Tanzania country manager
JPMorgan (JPM.US) approaches $1 trillion market capitalization, as competitor Bank of America declares: still very cheap!
According to Bank of America analysts, JPMorgan would still be considered cheap even if its market capitalization reached 1 trillion dollars.
Crypto prices
More
